Subtopic Deep Dive
Quinazolinone Anticancer Agents
Research Guide
What is Quinazolinone Anticancer Agents?
Quinazolinone anticancer agents are synthetic derivatives of the quinazolinone scaffold evaluated for antitumor activity through mechanisms like tubulin polymerization inhibition, apoptosis induction, and cell cycle arrest in cancer cell lines and xenografts.
Research spans synthesis of modified quinazolinones and their testing against leukemia, solid tumors via in vitro and in vivo models. Over 2,500 citations across key papers document structure-activity relationships (SAR) and mechanisms. Cao et al. (2005) reported 4(3H)-quinazolinone derivatives with dithiocarbamate side chains showing potent antitumor activity (344 citations).
Why It Matters
Quinazolinone derivatives target tubulin polymerization, as in Jiang et al. (1990) inhibiting L1210 leukemia cells, offering alternatives to taxanes with potentially lower toxicity (261 citations). Noolvi et al. (2011) identified quinazoline-quinoxaline hybrids active against multiple cancer lines, advancing SAR for clinical candidates (279 citations). Asif (2014) reviewed broad biological potential, supporting drug discovery pipelines for improved therapeutic indices in chemotherapy (202 citations). These agents fill gaps in kinase inhibitors and antimitotics used in breast, lung, and hematologic cancers.
Key Research Challenges
Optimizing Structure-Activity Relationships
Balancing substituents for potency versus selectivity remains difficult across cell lines. Cao et al. (2005) showed dithiocarbamate chains enhance activity but require refinement for specificity (344 citations). Jiang et al. (1990) noted entire quinazolinone core essential for tubulin inhibition, complicating modifications (261 citations).
Translating In Vitro to In Vivo Efficacy
Many derivatives excel in cell lines but fail xenografts due to pharmacokinetics. Noolvi et al. (2011) screened quinazolines in vitro but highlighted need for animal models (279 citations). Al-Obaid et al. (2008) used molecular modeling yet stressed in vivo validation gaps (194 citations).
Reducing Off-Target Toxicity
Broad biological activities increase side effects, limiting clinical progress. Asif (2014) cataloged diverse potentials but noted toxicity hurdles (202 citations). Negi and Ahmad (2017) reviewed quinazoline anticancer potential emphasizing safer profiles needed (195 citations).
Essential Papers
Synthesis and in vitro antitumor activity of 4(3H)-quinazolinone derivatives with dithiocarbamate side chains
Sheng‐Li Cao, Yuping Feng, Yuyang Jiang et al. · 2005 · Bioorganic & Medicinal Chemistry Letters · 344 citations
Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: Search for anticancer agent
Malleshappa N. Noolvi, Harun Patel, Varun Bhardwaj et al. · 2011 · European Journal of Medicinal Chemistry · 279 citations
Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization
Jack B. Jiang, David P. Hesson, Betsy A. Dusak et al. · 1990 · Journal of Medicinal Chemistry · 261 citations
A novel series of 2-styrylquinazolin-4(3H-ones which inhibited tubulin polymerization and the growth of L1210 murine leukemia cells was discovered. Extensive structure-activity relationship studies...
Chemical Characteristics, Synthetic Methods, and Biological Potential of Quinazoline and Quinazolinone Derivatives
Mohammad Asif · 2014 · International Journal of Medicinal Chemistry · 202 citations
The heterocyclic fused rings quinazoline and quinazolinone have drawn a huge consideration owing to their expanded applications in the field of pharmaceutical chemistry. Quinazoline and quinazolino...
An insight into the therapeutic potential of quinazoline derivatives as anticancer agents
Devendra Singh Negi, Irshad Ahmad · 2017 · MedChemComm · 195 citations
This article reviews the recent advances in the development of quinazoline derivatives as anticancer agents.
Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs☆
Abdulrahman M. Al‐Obaid, Sami G. Abdel‐Hamide, Hassan A. El‐Kashef et al. · 2008 · European Journal of Medicinal Chemistry · 194 citations
Quinazoline derivatives: synthesis and bioactivities
Dan Wang, Feng Gao · 2013 · Chemistry Central Journal · 189 citations
Reading Guide
Foundational Papers
Start with Jiang et al. (1990) for tubulin mechanism discovery (261 citations), then Cao et al. (2005) for high-citation dithiocarbamates (344 citations), Noolvi et al. (2011) for broad SAR (279 citations) to build core understanding.
Recent Advances
Study Negi and Ahmad (2017) therapeutic insights (195 citations), Badolato et al. (2018) DHQ scaffolds (129 citations), Wang and Gao (2013) bioactivity synthesis (189 citations) for advances.
Core Methods
Tubulin polymerization inhibition (Jiang 1990), in vitro cell line assays (Cao 2005, Noolvi 2011), molecular modeling (Al-Obaid 2008), SAR via substituent scans.
How PapersFlow Helps You Research Quinazolinone Anticancer Agents
Discover & Search
Research Agent uses searchPapers('quinazolinone anticancer tubulin inhibition') to retrieve Cao et al. (2005, 344 citations), then citationGraph reveals forward citations like Noolvi et al. (2011); findSimilarPapers on Jiang et al. (1990) uncovers styrylquinazolinone analogs; exaSearch('dithiocarbamate quinazolinone SAR') finds niche reviews.
Analyze & Verify
Analysis Agent applies readPaperContent on Cao et al. (2005) to extract IC50 data across cell lines, verifyResponse with CoVe cross-checks tubulin claims against Hamel et al. (1996), and runPythonAnalysis plots SAR trends from Noolvi et al. (2011) dose-response curves using pandas; GRADE grading scores evidence strength for apoptosis mechanisms.
Synthesize & Write
Synthesis Agent detects gaps in tubulin inhibitor SAR from Jiang et al. (1990) versus recent DHQ scaffolds (Badolato et al., 2018), flags contradictions in side-chain effects; Writing Agent uses latexEditText for SAR tables, latexSyncCitations integrates 10+ papers, latexCompile generates polished reviews, exportMermaid diagrams quinazolinone mechanisms.
Use Cases
"Analyze IC50 trends for dithiocarbamate quinazolinones across leukemia cell lines"
Research Agent → searchPapers → Analysis Agent → readPaperContent(Cao et al. 2005) → runPythonAnalysis(pandas plot IC50 vs substituents) → matplotlib dose-response graph exported as PNG.
"Draft LaTeX review on styrylquinazolinone tubulin inhibitors with citations"
Synthesis Agent → gap detection(Jiang et al. 1990 SAR gaps) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile → PDF with mechanism figures.
"Find GitHub code for quinazolinone QSAR modeling"
Research Agent → paperExtractUrls(Negi 2017) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis(reproduce RDKit descriptors on Asif 2014 structures).
Automated Workflows
Deep Research workflow scans 50+ quinazolinone papers via searchPapers → citationGraph, producing structured report with GRADE-scored mechanisms from Cao (2005) and Noolvi (2011). DeepScan applies 7-step CoVe analysis to Jiang et al. (1990) tubulin data, verifying SAR with Python plots. Theorizer generates hypotheses on DHQ modifications (Badolato 2018) for xenograft efficacy.
Frequently Asked Questions
What defines quinazolinone anticancer agents?
They are quinazolinone derivatives tested for antitumor effects via tubulin inhibition, apoptosis, and cycle arrest, as in Jiang et al. (1990) styryl series against L1210 cells (261 citations).
What are key synthesis methods?
Common routes include Niementowski reaction variants with aryl substitutions; Cao et al. (2005) used dithiocarbamate side chains on 4(3H)-quinazolinones (344 citations), Noolvi et al. (2011) quinazoline-quinoxaline hybrids (279 citations).
What are seminal papers?
Cao et al. (2005, 344 citations) on dithiocarbamates; Noolvi et al. (2011, 279 citations) on substituted quinazolines; Jiang et al. (1990, 261 citations) on antimitotic styrylquinazolinones.
What open problems exist?
Challenges include in vivo translation, toxicity reduction, and novel scaffolds beyond styryl/dithiocarbamates; Negi (2017) highlights clinical candidate gaps (195 citations).
Research Quinazolinone synthesis and applications with AI
PapersFlow provides specialized AI tools for Chemistry researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Code & Data Discovery
Find datasets, code repositories, and computational tools
See how researchers in Chemistry use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Quinazolinone Anticancer Agents with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Chemistry researchers